# Method Validation and Verification for Antimicrobial Susceptibility Testing ## Quick Answer - Validate new antimicrobial susceptibility testing (AST) methods before clinical use and verify established methods upon implementation to meet accreditation requirements. - Use reference strains from authenticated culture collections and compare results against CLSI or FDA reference methods for accuracy and reproducibility. - Verification does not replace full validation, and laboratories must document all performance data, limitations, and corrective actions for regulatory review. Antimicrobial susceptibility testing (AST) determines the minimum inhibitory concentration (MIC) of antimicrobial agents against bacterial isolates, guiding clinical treatment decisions and surveillance programs. The global threat of antimicrobial resistance (AMR) has intensified the need for reliable AST methods, as inaccurate results can lead to therapeutic failure or contribute to resistance spread. The World Health Organization identifies AMR as a major public health concern requiring coordinated surveillance and stewardship efforts across human, animal, and environmental sectors. Laboratory professionals face the practical challenge of implementing new AST systems while meeting accreditation standards that demand documented evidence of method performance. This article provides a structured template for validation and verification of AST methods, covering accuracy, precision, reproducibility, and comparison to reference methods, with examples applicable to common AST platforms. ## Understanding Validation versus Verification Validation and verification serve distinct purposes in laboratory quality management, though the terms are often used interchangeably in practice. Validation establishes that a new method performs as intended for its specified use, typically through comprehensive evaluation of accuracy, precision, and reproducibility. Verification confirms that an already validated method works correctly in a specific laboratory setting with local personnel, equipment, and patient populations. Accreditation bodies require both processes to be documented, but the scope and depth of each differ substantially. For AST methods, validation typically occurs during method development or when a laboratory introduces a fundamentally new testing platform. This process involves comparing the new method against an established reference method using a panel of well-characterized bacterial strains. The Clinical and Laboratory Standards Institute (CLSI) provides standards-based guidance for AST method development and evaluation, including protocols for broth microdilution, disk diffusion, and gradient diffusion methods. These standards outline acceptance criteria for categorical agreement, essential agreement, and reproducibility that laboratories must meet before implementing a new method. Verification applies when a laboratory adopts a commercially available AST system that has already been validated by the manufacturer. The laboratory must demonstrate that the system performs acceptably in its own environment with its own staff. Verification typically involves testing a smaller panel of quality control organisms and comparing results to expected values. The key distinction is that verification does not re-establish the method's fundamental performance characteristics but confirms that the laboratory can operate the method correctly. ## Regulatory and Accreditation Framework Laboratories performing AST for clinical decision-making operate under regulatory oversight that varies by jurisdiction. In the United States, clinical laboratories must comply with Clinical Laboratory Improvement Amendments (CLIA) regulations, which require documented validation or verification of all testing methods before patient specimens are reported. The Centers for Medicare and Medicaid Services (CMS) administers CLIA, and laboratories must maintain records demonstrating method performance for inspection by accrediting organizations such as the College of American Pathologists (CAP) or The Joint Commission. The FDA's Bacteriological Analytical Manual (BAM) provides official methods for food microbiology testing, including antimicrobial susceptibility testing procedures for foodborne pathogens. While BAM methods are primarily used in regulatory food testing, the quality principles apply broadly to laboratory practice. The manual emphasizes the importance of using standardized procedures, appropriate quality control organisms, and documented method performance. International laboratories may follow ISO 15189 standards for medical laboratory quality and competence, which include specific requirements for method validation and verification. The ISO standard requires laboratories to validate non-standard methods, laboratory-developed methods, and modified standard methods, while verifying that standard methods perform acceptably in their specific context. Accreditation bodies assess compliance through on-site inspections and document review. ## Core Performance Characteristics for AST Methods ### Accuracy and Essential Agreement Accuracy in AST refers to how closely the new method's results match those of the reference method. Essential agreement (EA) is calculated as the percentage of results where the MIC values from the test method fall within one doubling dilution of the reference method result. For categorical agreement (CA), results are classified as susceptible, intermediate, or resistant according to established breakpoints, and the percentage of concordant classifications is calculated. Acceptance criteria for accuracy typically require at least 90% essential agreement and at least 90% categorical agreement for each antimicrobial-organism combination. Discrepancies are categorized as very major errors (false susceptible), major errors (false resistant), or minor errors (susceptible versus intermediate or intermediate versus resistant discrepancies). Very major errors are the most clinically significant because they could lead to treatment failure with an ineffective antimicrobial. ### Precision and Reproducibility Precision measures the closeness of agreement between repeated measurements under the same conditions. Within-laboratory precision is assessed by testing the same isolates multiple times on different days, with different operators, and with different reagent lots. Between-laboratory reproducibility is evaluated through collaborative studies where multiple laboratories test identical panels of organisms using the same method. For AST methods, acceptable precision typically requires that MIC results vary by no more than one doubling dilution across repeated testing. Reproducibility studies should include organisms with MIC values near clinically relevant breakpoints, as these are the most challenging to classify consistently. The evaluation should also include organisms with known resistance mechanisms to ensure the method detects resistance reliably. ### Comparison to Reference Methods The reference method for AST is broth microdilution as described in CLSI standards, which provides quantitative MIC results. Disk diffusion is a qualitative method that classifies organisms as susceptible, intermediate, or resistant based on zone diameter measurements. Gradient diffusion methods provide quantitative MIC results using a plastic strip with a continuous antimicrobial concentration gradient. When comparing a new method to a reference method, laboratories must test a sufficient number of isolates to achieve statistical confidence in the comparison. The isolate panel should include organisms with a range of susceptibility patterns, including resistant strains, and should reflect the types of organisms the laboratory expects to test in routine practice. The panel should also include quality control organisms with known MIC values to monitor method performance throughout the comparison. ## At a Glance: Validation and Verification Comparison | Aspect | Full Validation | Verification | |--------|----------------|--------------| | Purpose | Establish method performance for intended use | Confirm method works in specific laboratory | | Isolate panel | Large, diverse panel including resistant strains | Smaller panel with quality control organisms | | Comparison method | Reference method required | Expected values or manufacturer claims | | Performance criteria | EA ≥ 90%, CA ≥ 90%, reproducibility within one dilution | Results within acceptable range for QC organisms | | Documentation | Comprehensive validation report | Verification record with results and sign-off | | Regulatory requirement | Required for new or modified methods | Required for established methods upon implementation | ## Practical Implementation Steps ### Step 1: Define the Scope of Validation or Verification Before beginning any validation or verification activity, the laboratory must clearly define the scope of the evaluation. This includes identifying the specific AST method, the antimicrobial agents to be tested, the organism types to be included, and the intended clinical use of the results. The scope should also specify whether the method will be used for routine clinical testing, surveillance, or research purposes, as this affects the performance requirements. The laboratory director or designated quality manager should document the scope in a validation or verification plan that outlines the specific activities to be performed, the personnel responsible, and the timeline for completion. This plan serves as the roadmap for the evaluation and provides evidence of deliberate method assessment. ### Step 2: Select Appropriate Reference Strains and Clinical Isolates Authenticated reference strains from culture collections such as the American Type Culture Collection (ATCC) provide the foundation for AST method evaluation. These strains have documented MIC values for various antimicrobial agents and serve as quality control organisms for monitoring method performance. The ATCC collection includes strains specifically designated for AST quality control, such as Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853. Clinical isolates for the validation panel should be selected to represent the diversity of organisms and resistance patterns the laboratory encounters in routine practice. The panel should include organisms with MIC values spanning the range from susceptible to resistant for each antimicrobial agent tested. Organisms with known resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) producers or carbapenem-resistant strains, should be included to challenge the method's ability to detect clinically significant resistance. ### Step 3: Establish Testing Protocols and Operator Training Standardized testing protocols are essential for reproducible AST results. The laboratory should adopt protocols from CLSI standards or the manufacturer's instructions for the specific AST system being evaluated. These protocols specify inoculum preparation, media requirements, incubation conditions, and result interpretation criteria. All personnel performing AST must receive documented training on the specific method before participating in validation or verification studies. Training should include hands-on practice with the method, instruction on quality control procedures, and assessment of competency through direct observation and testing of known organisms. Training records should be maintained as part of the laboratory's quality documentation. ### Step 4: Execute the Validation or Verification Study The validation or verification study should follow the approved plan and include the specified number of isolates and replicates. For validation studies, each isolate should be tested in triplicate on separate days to assess within-laboratory precision. For verification studies, quality control organisms should be tested according to the manufacturer's recommendations, typically over a minimum of 20 to 30 test days. During the study, the laboratory should document all results, including any deviations from the testing protocol. Deviations should be investigated and documented, as they may affect the validity of the results. The laboratory should also monitor environmental conditions, such as incubation temperature and humidity, to ensure they remain within acceptable ranges throughout the study. ### Step 5: Analyze Results and Determine Acceptance Results from the validation or verification study should be analyzed according to the acceptance criteria established in the validation plan. For validation studies, the analysis should include calculation of essential agreement, categorical agreement, and reproducibility statistics. For verification studies, the analysis should confirm that quality control results fall within acceptable ranges for the specified organisms and antimicrobial agents. If the results meet the acceptance criteria, the laboratory can proceed with implementing the method for routine use. If the results do not meet the acceptance criteria, the laboratory must investigate the cause of the failure, implement corrective actions, and repeat the evaluation. The investigation should consider potential sources of error, including operator technique, reagent quality, equipment calibration, and environmental conditions. ### Step 6: Document the Validation or Verification Report The final validation or verification report should provide a comprehensive summary of the evaluation, including the scope, methods, results, and conclusions. The report should include the raw data from the study, the statistical analysis, and the acceptance criteria used to evaluate the results. Any deviations from the approved plan and the corrective actions taken should be documented. The report should be reviewed and approved by the laboratory director or designated quality manager before the method is implemented for routine use. The approved report becomes part of the laboratory's quality documentation and should be retained according to the laboratory's record retention policy. ## Records and Measurements for AST Method Evaluation | Measurement | Purpose | Frequency | Acceptance Criterion | |-------------|---------|-----------|---------------------| | Quality control MIC values | Monitor method performance | Each day of testing | Within CLSI or manufacturer ranges | | Essential agreement | Compare new method to reference | During validation | ≥ 90% within one dilution | | Categorical agreement | Assess clinical classification concordance | During validation | ≥ 90% agreement | | Reproducibility | Assess between-run and between-day variation | During validation | ≥ 95% within one dilution | | Operator competency | Verify staff proficiency | Annually and after training | Successful testing of QC organisms | ## Common Failure Patterns in AST Method Evaluation ### Inadequate Isolate Panel Composition A common failure in AST method validation is using an isolate panel that does not adequately represent the range of susceptibility patterns the method will encounter in routine use. Panels dominated by susceptible organisms may not challenge the method's ability to detect resistance, leading to an overestimation of method performance. Conversely, panels with too many resistant organisms may produce results that do not reflect typical clinical scenarios. Laboratories should design isolate panels to include organisms with MIC values distributed across the range for each antimicrobial agent, with particular attention to organisms with MIC values near breakpoints. The panel should also include organisms with diverse resistance mechanisms, such as ESBL producers, carbapenemase producers, and methicillin-resistant staphylococci, to ensure the method detects clinically significant resistance. ### Insufficient Replication for Statistical Confidence Validation studies require sufficient replication to achieve statistical confidence in the results. Testing each isolate only once may not detect run-to-run variation, leading to an underestimation of method variability. The number of replicates required depends on the expected variability of the method and the desired level of statistical confidence. For reproducibility studies, each isolate should be tested at least three times on separate days to assess day-to-day variation. For between-laboratory studies, each isolate should be tested by multiple laboratories to assess inter-laboratory variation. The statistical analysis should include calculation of confidence intervals for the performance metrics to provide a measure of the precision of the estimates. ### Quality Control Failures During Verification Verification studies often fail because quality control organisms produce results outside acceptable ranges. This can occur for several reasons, including improper inoculum preparation, contaminated media, incorrect incubation conditions, or degraded antimicrobial agents. Quality control failures during verification indicate that the laboratory cannot reliably operate the method, and the verification cannot be completed until the issue is resolved. When quality control failures occur, the laboratory should investigate the cause, document the investigation, and implement corrective actions. The investigation should include review of the testing procedure, inspection of reagents and media, and verification of equipment calibration. After corrective actions are implemented, quality control testing should be repeated to confirm the issue is resolved before proceeding with the verification study. ### Inadequate Documentation of Deviations Accreditation inspectors frequently identify inadequate documentation of deviations from approved protocols as a deficiency. Laboratories must document all deviations from the validation or verification plan, including the nature of the deviation, the reason it occurred, and the impact on the validity of the results. Undocumented deviations raise questions about the reliability of the entire evaluation. The laboratory should establish a process for documenting and reviewing deviations during validation and verification studies. This process should include a log of deviations, a review by the laboratory director or quality manager, and a determination of whether the deviation affects the validity of the results. If the deviation could affect the results, the affected tests should be repeated. ## Biosafety Considerations for AST Testing Antimicrobial susceptibility testing involves handling bacterial cultures that may include clinically significant pathogens, including multidrug-resistant organisms. The CDC and NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) provides guidance for risk assessment and containment of biological agents. Laboratories must conduct a risk assessment for the organisms they handle and implement appropriate biosafety practices. Most AST testing involves organisms classified at Biosafety Level 2 (BSL-2), which requires standard microbiological practices, personal protective equipment, and a biological safety cabinet for procedures that may generate aerosols. Organisms with enhanced pathogenicity or those that are highly drug-resistant may require additional containment measures. The laboratory's biosafety manual should specify the required practices for handling the organisms tested in the AST method. Decontamination of waste materials is an essential component of biosafety in AST testing. All cultures, media, and contaminated materials must be decontaminated before disposal, typically through autoclaving or chemical disinfection. The laboratory should have documented procedures for waste decontamination and should verify that these procedures are effective through routine monitoring. ## Antimicrobial Resistance Surveillance Context AST method validation and verification support antimicrobial resistance surveillance programs at local, national, and global levels. The World Health Organization coordinates global surveillance of antimicrobial resistance through the Global Antimicrobial Resistance and Use Surveillance System (GLASS), which collects standardized data from member countries. Reliable AST methods are essential for generating comparable data across laboratories and countries. The NCBI Pathogen Detection system integrates bacterial genomic data with antimicrobial resistance information to support surveillance and outbreak investigations. Whole-genome sequencing can predict antimicrobial resistance from genetic data, but phenotypic AST remains essential for confirming resistance and determining clinically relevant susceptibility categories. Laboratories contributing data to surveillance programs must ensure their AST methods meet quality standards to produce reliable data. Surveillance data from clinical and non-clinical sources reveals the spread of antimicrobial resistance beyond healthcare settings. Studies have identified multidrug-resistant Acinetobacter baumannii in ready-to-eat foods, indicating that food can serve as a reservoir for resistant organisms. Similarly, antimicrobial resistance in Escherichia coli from companion animals demonstrates the importance of a One Health approach to resistance surveillance. Reliable AST methods are essential for detecting and monitoring resistance across these diverse settings. ## Molecular Methods and Their Relationship to Phenotypic AST Molecular methods for detecting antimicrobial resistance genes complement phenotypic AST but do not replace it. Polymerase chain reaction (PCR) and whole-genome sequencing can detect specific resistance genes, such as blaOXA-48 in carbapenem-resistant Klebsiella pneumoniae or ESBL genes in Acinetobacter baumannii. These methods provide rapid detection of resistance mechanisms and can support infection control decisions. However, molecular methods have limitations. The presence of a resistance gene does not always correlate with phenotypic resistance, as gene expression can vary. Conversely, phenotypic resistance can occur through mechanisms not detected by targeted gene assays, such as efflux pumps or porin mutations. Phenotypic AST remains the standard for determining clinically relevant susceptibility categories and guiding treatment decisions. Rapid molecular methods, such as the RPA-CRISPR/Cas12a platform for detecting Klebsiella pneumoniae and carbapenem-resistant strains, offer point-of-care testing capabilities that reduce reliance on sophisticated laboratory equipment. These methods require validation against reference methods, including microbial culture and quantitative PCR, to establish their performance characteristics. The validation process for molecular methods follows similar principles to phenotypic AST validation, including assessment of sensitivity, specificity, and reproducibility. ## Options and Tradeoffs in AST Method Selection ### Broth Microdilution Broth microdilution is the reference method for AST and provides quantitative MIC results. The method involves preparing serial dilutions of antimicrobial agents in microtiter plates, inoculating with a standardized bacterial suspension, and incubating under controlled conditions. Broth microdilution is flexible, allowing testing of multiple antimicrobial agents against a single isolate in a single plate. The primary limitation of broth microdilution is the labor and time required for preparation and interpretation. Commercial broth microdilution panels reduce the preparation burden but may have limited antimicrobial agent selections. The method also requires careful attention to inoculum preparation and quality control to ensure reproducible results. ### Disk Diffusion Disk diffusion, also known as the Kirby-Bauer method, is a qualitative method that classifies organisms as susceptible, intermediate, or resistant based on zone diameters. The method involves placing antimicrobial-impregnated disks on an agar plate inoculated with a standardized bacterial suspension, incubating, and measuring the zone of inhibition. Disk diffusion is simple, cost-effective, and flexible, allowing laboratories to select specific antimicrobial agents for testing. The method is well-suited for organisms that grow well on standard media and for laboratories with limited resources. However, disk diffusion does not provide quantitative MIC results, which may be needed for certain clinical decisions or for surveillance programs that require MIC data. ### Gradient Diffusion Gradient diffusion methods use plastic strips impregnated with a continuous gradient of antimicrobial agent to determine MIC values. The strip is placed on an inoculated agar plate, and the MIC is read at the point where the ellipse of inhibition intersects the strip. Gradient diffusion provides quantitative MIC results with the simplicity of a disk diffusion method. The method is particularly useful for testing fastidious organisms or for determining MIC values for specific clinical decisions. The primary limitation is the cost of the strips, which may be higher than other methods for high-volume testing. ### Automated Systems Automated AST systems provide rapid results with minimal hands-on time, making them attractive for high-volume clinical laboratories. These systems use various technologies, including turbidimetric monitoring, fluorometric detection, or colorimetric indicators, to determine MIC values. Automated systems typically include software for result interpretation and quality control monitoring. The primary tradeoff of automated systems is the initial capital investment and ongoing reagent costs. Laboratories must also validate or verify each automated system according to regulatory requirements, which adds to the implementation burden. However, the efficiency gains and reduced labor requirements often justify the investment for laboratories with high testing volumes. ## Common Failure Patterns in Routine AST Operations ### Inoculum Preparation Errors Inoculum preparation is a critical step in AST that significantly affects results. The standard inoculum for broth microdilution and disk diffusion is approximately 1.5 x 10^8 colony-forming units per milliliter, equivalent to a 0.5 McFarland standard. Errors in inoculum preparation can lead to inaccurate MIC results, with too high an inoculum producing falsely resistant results and too low an inoculum producing falsely susceptible results. Laboratories should verify the accuracy of their inoculum preparation methods through periodic comparison to McFarland standards and through quality control testing. Automated inoculum preparation devices can reduce variability but require regular calibration and maintenance. Personnel should receive training on proper inoculum preparation technique and should be assessed for competency. ### Media and Reagent Quality Issues The quality of culture media and antimicrobial reagents directly affects AST results. Media must be prepared according to specifications, with appropriate pH, agar concentration, and supplements. Antimicrobial disks and strips must be stored under appropriate conditions and used before their expiration dates. Laboratories should implement quality control procedures for media and reagents, including testing each new lot before use in patient testing. Quality control testing should include organisms with known susceptibility patterns to verify that the media and reagents perform as expected. Records of quality control testing should be maintained for inspection. ### Incubation Condition Variability Incubation conditions, including temperature, atmosphere, and duration, affect bacterial growth and antimicrobial activity. Most AST methods require incubation at 35 to 37 degrees Celsius for 16 to 24 hours, with some organisms requiring extended incubation or specific atmospheric conditions. Laboratories should monitor incubation conditions regularly and document any deviations. Incubator temperature should be verified daily, and carbon dioxide incubators should be monitored for appropriate gas concentration. Organisms with special incubation requirements, such as fastidious organisms requiring increased carbon dioxide, should be identified and tested according to the appropriate protocol. ## Professional Escalation Criteria Laboratory professionals should escalate AST method issues to the laboratory director or quality manager when certain conditions are met. These include repeated quality control failures that do not resolve after corrective action, discrepancies between AST results and expected resistance patterns for specific organisms, and results that suggest the method is not performing as validated. Repeated quality control failures may indicate a systemic problem with the method, reagents, or equipment that requires investigation beyond routine troubleshooting. The laboratory director should be notified when quality control failures occur on multiple consecutive test days or when corrective actions do not resolve the issue. Discrepancies between AST results and expected resistance patterns may indicate problems with organism identification, contamination, or method performance. For example, a carbapenem-susceptible result for an organism that is expected to be carbapenem-resistant based on local epidemiology should be investigated before reporting. The laboratory should have procedures for verifying unusual or unexpected AST results. Results that suggest the method is not performing as validated should be escalated immediately. This includes results that are consistently outside expected ranges for quality control organisms or results that show poor reproducibility across repeated testing. The laboratory should suspend patient testing with the method until the issue is resolved and the method is re-verified. ## Evidence Limitations and Interpretation The evidence base for AST method validation and verification draws from multiple sources, including standards documents, peer-reviewed studies, and regulatory guidance. Each source has limitations that should be considered when interpreting results. Standards documents from CLSI provide consensus-based recommendations for AST methods and quality control. These standards are developed through a rigorous process involving expert review and public comment, but they may not address all clinical scenarios or emerging resistance mechanisms. Laboratories should stay current with standard updates and implement changes as required. Peer-reviewed studies on AST methods provide evidence of method performance in specific contexts. These studies may have limitations related to sample size, isolate selection, or generalizability to other settings. Laboratories should consider the relevance of study findings to their specific patient populations and testing conditions. Regulatory guidance from agencies such as the FDA and CMS establishes minimum requirements for method validation and verification. These requirements are designed to ensure patient safety but may not address all aspects of method performance. Laboratories should implement additional quality measures as appropriate for their specific context. ## Quality Control and Proficiency Testing Quality control is an essential component of AST method validation and verification. Quality control organisms with documented MIC values are tested alongside patient specimens to monitor method performance. The Clinical and Laboratory Standards Institute provides tables of acceptable quality control ranges for various organisms and antimicrobial agents. Quality control testing should be performed each day of patient testing, with results documented and reviewed. Quality control failures must be investigated and resolved before patient results are reported. The laboratory should have procedures for handling quality control failures, including repeat testing, investigation of potential causes, and documentation of corrective actions. Proficiency testing provides an external assessment of laboratory performance. Accrediting organizations require laboratories to participate in proficiency testing programs that provide unknown specimens for testing and compare results across participating laboratories. Proficiency testing results should be reviewed by the laboratory director, and unsatisfactory results should be investigated and corrected. ## Method Modification and Re-Validation Laboratories may modify validated AST methods to meet specific needs, such as testing additional antimicrobial agents, using different media, or adapting the method for new organism types. Any modification to a validated method requires re-validation to ensure the modified method performs acceptably. The scope of re-validation depends on the nature of the modification. Minor modifications, such as changing the source of a reagent, may require only verification that the modified method produces equivalent results. Major modifications, such as changing the testing format or adding new organism types, may require full validation with a comprehensive isolate panel. Laboratories should document all method modifications and the associated validation or verification activities. The documentation should include the rationale for the modification, the validation or verification results, and the approval of the laboratory director. This documentation provides evidence of ongoing method quality and supports accreditation inspections. ## Training and Competency Assessment Personnel performing AST must have appropriate training and demonstrated competency. Training should cover the principles of AST, the specific method being used, quality control procedures, and result interpretation. New personnel should complete training before performing patient testing, and all personnel should receive ongoing training as methods or standards change. Competency assessment should be performed at least annually and after any training or method changes. Competency assessment may include direct observation of testing, review of quality control results, and testing of unknown specimens. The laboratory should document competency assessments and address any deficiencies identified. The American Society for Microbiology provides educational resources for microbiology laboratory professionals, including training materials and guidance on laboratory practice. These resources support the development of a skilled workforce capable of performing reliable AST and contributing to antimicrobial resistance surveillance. ## Future Directions in AST Method Validation The field of antimicrobial susceptibility testing is evolving with advances in technology and changing clinical needs. Rapid AST methods that provide results in hours instead of days are being developed to support timely treatment decisions. These methods require validation against reference methods to establish their performance characteristics. Whole-genome sequencing is increasingly used to predict antimicrobial resistance from genomic data. While sequencing can identify resistance genes, phenotypic AST remains essential for confirming resistance and determining clinically relevant susceptibility categories. The integration of genomic and phenotypic data requires careful validation to ensure reliable predictions. Point-of-care AST methods, such as the RPA-CRISPR/Cas12a platform for detecting carbapenem-resistant Klebsiella pneumoniae, offer the potential for rapid testing outside traditional laboratory settings. These methods require validation against reference methods and consideration of their limitations, including the need for specific equipment and trained personnel. Laboratories should monitor developments in AST technology and evaluate new methods as they become available. The validation and verification principles described in this article apply to new methods, ensuring that they meet the same quality standards as established methods. ## Frequently Asked Questions ### What is the difference between method validation and method verification in AST? Validation establishes that a new AST method performs as intended through comprehensive evaluation of accuracy, precision, and reproducibility against a reference method. Verification confirms that an already validated method works correctly in a specific laboratory with local personnel, equipment, and patient populations. Validation uses a large, diverse isolate panel, while verification typically uses a smaller panel with quality control organisms. ### How many isolates are needed for AST method validation? The number of isolates needed depends on the method being validated and the statistical confidence required. Validation studies typically include at least 100 to 300 isolates to achieve adequate representation of susceptibility patterns and resistance mechanisms. The isolate panel should include organisms with MIC values distributed across the range for each antimicrobial agent, with particular attention to organisms with MIC values near breakpoints. ### What are the acceptance criteria for AST method validation? Acceptance criteria for AST method validation typically require at least 90% essential agreement and at least 90% categorical agreement for each antimicrobial-organism combination. Reproducibility should be at least 95% within one doubling dilution across repeated testing. Very major errors, where the test method reports susceptible when the reference method reports resistant, should be minimized because they could lead to treatment failure. ### How often should quality control testing be performed for AST? Quality control testing should be performed each day of patient testing for AST methods. Quality control organisms with documented MIC values are tested alongside patient specimens to monitor method performance. Quality control failures must be investigated and resolved before patient results are reported. Some laboratories may reduce quality control frequency to weekly if they can demonstrate consistent performance over time, but this requires documented justification. ### What should be done when AST quality control results are out of range? When quality control results are out of range, the laboratory should investigate the cause, document the investigation, and implement corrective actions. The investigation should include review of the testing procedure, inspection of reagents and media, and verification of equipment calibration. Patient results from the affected testing period should not be reported until the issue is resolved and quality control testing confirms acceptable performance. ### Can molecular methods replace phenotypic AST? Molecular methods for detecting antimicrobial resistance genes complement phenotypic AST but do not replace it. The presence of a resistance gene does not always correlate with phenotypic resistance, and phenotypic resistance can occur through mechanisms not detected by targeted gene assays. Phenotypic AST remains the standard for determining clinically relevant susceptibility categories and guiding treatment decisions. ### What biosafety precautions are needed for AST testing? Most AST testing involves organisms classified at Biosafety Level 2, which requires standard microbiological practices, personal protective equipment, and a biological safety cabinet for procedures that may generate aerosols. Laboratories must conduct a risk assessment for the organisms they handle and implement appropriate containment measures. All cultures, media, and contaminated materials must be decontaminated before disposal. ### How should laboratories document AST method validation or verification? Laboratories should document the validation or verification plan, the results of the evaluation, and the conclusions in a comprehensive report. The report should include the scope, methods, raw data, statistical analysis, and acceptance criteria. Any deviations from the approved plan and corrective actions should be documented. The report should be reviewed and approved by the laboratory director and retained according to the laboratory's record retention policy. ## Related Bacteriology Guides - [Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens](/knowledge/bacteria/general/biological-foundation-models-for-antimicrobial-peptide-discovery-in-veterinary-pathogens) - [Bacterial Infections in Poultry: Clinical Manifestations, Diagnosis, and Antimicrobial Therapy](/knowledge/bacteria/avian-bacteria/poultry-bacterial-infection) - [Chlamydiosis in Birds: Clinical Presentation and Advanced Diagnostic Methods](/knowledge/bacteria/avian-bacteria/chlamydiosis-birds-clinical-presentation-advanced-diagnostic-methods) - [Swine Dysentery: Age Susceptibility, Causative Agent, and Clinical Management in Pigs](/knowledge/bacteria/livestock-bacteria/swine-dysentery-age-causative-agent) - [Colibacillosis in Chickens: Pathogenesis, Clinical Signs, and Antimicrobial Treatment](/knowledge/bacteria/avian-bacteria/chicken-e-coli-colibacillosis-treatment) ## References and Further Reading - [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH. - [Microbiology Resources](https://asm.org/). American Society for Microbiology. - [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance). World Health Organization. - [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam). U.S. Food and Drug Administration. - [Antimicrobial Susceptibility Testing](https://clsi.org/standards/products/microbiology). Clinical and Laboratory Standards Institute. - [Culture Collections](https://www.atcc.org/). American Type Culture Collection. - [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens). National Center for Biotechnology Information. - [Visual detection platform based on RPA-CRISPR/Cas12a for Klebsiella pneumoniae and Carbapenem-resistant Klebsiella pneumoniae in clinical and food safety settings.](https://doi.org/10.3389/fcimb.2026.1817859). 2026. - [Occurrence and Antimicrobial Susceptibility Pattern of Clinical <,i>,Escherichia coli<,/i>, Isolates from Dogs in Grenada, West Indies.](https://doi.org/10.3390/antibiotics15050522). 2026. - [Antimicrobial Resistance in <,i>,Acinetobacter baumannii<,/i>, Isolated from Ready-to-Eat Foods in Saudi Arabia.](https://doi.org/10.3390/pathogens15030261). 2026. - [Phenotypic and Genotypic Detection of Extended-Spectrum Beta-Lactamase (ESBL) and Metallo-Beta-Lactamase (MBL) Genes in Multidrug-Resistant Acinetobacter baumannii Isolates Derived From Diabetic Foot Ulcer Patients.](https://doi.org/10.7759/cureus.109329). 2026. > This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.